Active Ingredient History
Levodopa (L-DOPA) was first isolated from seedlings of Vicia faba by Marcus Guggenheim in 1913. Levodopa, a dopamine precursor, is an effective and well-tolerated dopamine replacement agent used to treat Parkinson's disease. Oral levodopa has been widely used for over 40 years, often in combination with a dopa-decarboxylase inhibitor carbidopa, which reduces many treatment complications, extending its half-life and increasing levodopa availability to the brain. Entacapone, a catechol-O-methyltransferase inhibitor, can also be used to improve the bioavailability of levodopa, especially when used in conjunction with a carbidopa. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
Combination drugs
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Acute Pain (Phase 4)
Albinism (Phase 2)
Albinism, Oculocutaneous (Phase 2)
Alcohol Drinking (Phase 4)
Alzheimer Disease (Phase 4)
Amblyopia (Phase 3)
Amyotrophic Lateral Sclerosis (Phase 1)
Analgesics, Opioid (Phase 2)
Angelman Syndrome (Phase 2/Phase 3)
Anhedonia (Phase 4)
Aphasia (Phase 4)
Aphasia, Broca (Phase 2/Phase 3)
Asthma (Phase 1)
Autonomic Nervous System Diseases (Phase 3)
Back Injuries (Phase 2)
Back Pain (Phase 2)
Brain Diseases (Phase 2)
Brain Injuries, Traumatic (Early Phase 1)
Bunion (Phase 2)
Central Nervous System Diseases (Phase 2)
Cerebral Palsy (Phase 4)
Chronic Pain (Phase 2)
Cocaine-Related Disorders (Phase 2/Phase 3)
Cognitive Dysfunction (Phase 4)
Consciousness Disorders (Early Phase 1)
Depression (Phase 4)
Depressive Disorder (Phase 4)
Depressive Disorder, Major (Phase 4)
Depressive Disorder, Treatment-Resistant (Phase 2)
Dermatology (Phase 1)
Diabetic Retinopathy (Early Phase 1)
Dopamine (Phase 4)
Dopamine beta-Hydroxylase (Phase 3)
Dyskinesias (Phase 4)
Dyslexia (Phase 4)
Dysthymic Disorder (Phase 4)
Fasting (Phase 1)
Gait (Phase 4)
Haloperidol (Phase 1)
Healthy Volunteers (Phase 4)
Hypotension, Orthostatic (Phase 3)
Ischemic Stroke (Phase 3)
Joint Diseases (Phase 4)
Levodopa (Phase 2)
Macula Lutea (Phase 2)
Macular Degeneration (Phase 2)
Motor Activity (Phase 3)
Motor Neuron Disease (Phase 1)
Movement Disorders (Phase 2)
Narcotics (Phase 2)
Neurodegenerative Diseases (Phase 2)
Opioid-Related Disorders (Phase 2)
Optic Neuropathy, Ischemic (Phase 4)
Orthostatic Intolerance (Phase 3)
Pain (Phase 2)
Parkinsonian Disorders (Phase 2)
Pharmacokinetics (Phase 1)
Placebos (Phase 1)
Pure Autonomic Failure (Phase 1)
Restless Legs Syndrome (Phase 3)
Retina (Phase 2)
Retinal Diseases (Phase 4)
Retinitis Pigmentosa (Phase 2)
Schizophrenia (Phase 2)
Signs and Symptoms (Phase 4)
Smoking (Phase 1)
Spinal Cord Injuries (Phase 2/Phase 3)
Stress Disorders, Post-Traumatic (Phase 4)
Stroke (Phase 4)
Stroke Rehabilitation (Phase 3)
Therapeutic Equivalency (Phase 1)
Toes (Phase 2)
Treatment Adherence and Compliance (Phase 4)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
